Royce & Associates LP Liquidia Corp Transaction History

Royce & Associates LP

  • $10.5 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024
BUY
$11.35 - $16.73 $272,400 - $401,520
24,000 New
24,000 $354,000
Q3 2020

Nov 12, 2020
SELL
$4.34 - $8.28 $737,800 - $1.41 Million
-170,000 Closed
0 $0
Q2 2020

Aug 07, 2020
BUY
$4.86 - $11.44 $826,200 - $1.94 Million
170,000 New
170,000 $1.43 Million

Others Institutions Holding LQDA

# of Institutions
174
Shares Held
44.4M
Call Options Held
1.55M
Put Options Held
1.52M
View Full List

About Liquidia Corp

LQDA Quotes by TradingView
  • Ticker LQDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,362,300
  • Market Cap $1.01B
  • Description
  • Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...
More about LQDA
Track This Portfolio

Track Royce & Associates LP Portfolio

Follow Royce & Associates LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royce & Associates LP, based on Form 13F filings with the SEC.

News

Stay updated on Royce & Associates LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email